ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO1660

Integration of Plasma Proteomics and Metabolomics Revealed Multiple Protein-Metabolite Networks in Steroid-Resistant Nephrotic Pediatric Patients

Session Information

Category: Glomerular Diseases

  • 1201 Glomerular Diseases: Fibrosis and Extracellular Matrix

Authors

  • Bhayana, Sagar, Nationwide Children's Hospital, Columbus, Ohio, United States
  • Zhao, Yue, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
  • Merchant, Michael, University of Louisville, Louisville, Kentucky, United States
  • Cummins, Timothy, University of Louisville, Louisville, Kentucky, United States
  • Pathmasiri, Wimal, University of North Carolina System, Chapel Hill, North Carolina, United States
  • Mcritchie, Susan, University of North Carolina System, Chapel Hill, North Carolina, United States
  • Sumner, Susan Jenkins, University of North Carolina System, Chapel Hill, North Carolina, United States
  • Klein, Jon B., University of Louisville, Louisville, Kentucky, United States
  • Smoyer, William E., Nationwide Children's Hospital, Columbus, Ohio, United States
Background

Nephrotic Syndrome (NS) is a common glomerular disease in children. Glucocorticoids (GC) are the mainstay of NS treatment, but steroid-resistant NS (SRNS) develops in 5-20% of children, dramatically increasing risk for progressive CKD vs. children with steroid sensitive NS (SSNS). There are no validated biomarkers able to predict which children will have SRNS. Here, we used previously published plasma proteomic and metabolomic profiles from children with SSNS and SRNS to test the hypothesis that integrating proteomic + metabolomic data could identify biomarkers and/or targets to define SRNS pathways that were not identified in the individual datasets.

Methods

Proteomic data from 15 paired NS plasma samples (n=7 SSNS; n=8 SRNS) and relative concentrations of metabolites estimated from plasma NMR metabolomics data from the same subjects underwent joint pathway analyses using MetaboAnalyst 5.0. software. Fold change (FC) was calculated as the ratio of pre-treatment to post-treatment for each protein and metabolite, and then log2 transformed. Proteins with Log2FC<-10 or Log2FC>10 and metabolites with Log2FC<-1 or Log2FC>1 were included in the analyses.

Results

Pathway analyses of proteomic data identified “ECM receptor interaction” and “focal adhesion” as the most significantly up- and down-regulated pathways in SRNS vs. SSNS, whereas “Valine, Leucine & Isoleucine biosynthesis”, and “Glycosaminoglycan biosynthesis” were the most up- and down-regulated metabolic pathways in SRNS, respectively. Integrated proteomic + metabolomic pathway analyses identified 3 metabolic pathways that were perturbed in SRNS but not in SSNS: 1) “Nicotinate & Nicotinamide” pathway was perturbed in 50% of SRNS subjects (4 SRNS vs. 0 SSNS), 2) “Butanoate” was perturbed in 37.5% of SRNS subjects (3 vs. 0), and 3) “Glycine, Serine & Threonine” metabolism was perturbed in 25% of SRNS subjects (2 vs. 0).

Conclusion

Integrating proteomic + metabolomic data from children with SRNS vs. SSNS have identified multiple pathways and protein-metabolite linkages with potential to become future candidate biomarkers or drug targets of SRNS